HCAT(HCAT)
HCAT
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E | FY2028E |
|---|---|---|---|
| Revenue Avg | $263M | $247M | $247M |
| Low | $262M | $233M | $240M |
| High | $264M | $272M | $254M |
| EBITDA Avg | $-40M | $-38M | $-38M |
| Low | $-40M | $-42M | $-39M |
| High | $-40M | $-36M | $-37M |
| EBIT Avg | $-75M | $-70M | $-70M |
| Low | $-75M | $-77M | $-72M |
| High | $-74M | $-66M | $-68M |
| Net Income Avg | $4M | $9M | $2M |
| Low | $-15M | $-23M | $2M |
| High | $18M | $35M | $2M |
| EPS Avg | $0.04 | $0.09 | $0.03 |
| Low | $-0.21 | $-0.32 | $0.02 |
| High | $0.25 | $0.51 | $0.03 |
| Analysts (Rev / EPS) | 5 / 4 | 5 / 4 | 2 / 1 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $63M | $61M | $60M | $60M | $59M | $58M |
| Low | $63M | $60M | $60M | $59M | $59M | $58M |
| High | $63M | $61M | $61M | $60M | $60M | $59M |
| EBITDA Avg | $-10M | $-9M | $-9M | $-9M | $-9M | $-9M |
| Low | $-10M | $-9M | $-9M | $-9M | $-9M | $-9M |
| High | $-10M | $-9M | $-9M | $-9M | $-9M | $-9M |
| EBIT Avg | $-18M | $-17M | $-17M | $-17M | $-17M | $-16M |
| Low | $-18M | $-17M | $-17M | $-17M | $-17M | $-17M |
| High | $-18M | $-17M | $-17M | $-17M | $-17M | $-16M |
| Net Income Avg | $-40,361 | $-10,598 | $-809,411 | $-733,189 | $-693,263 | $-442,817 |
| Low | $-3M | $-10,738 | $-820,071 | $-742,844 | $-702,393 | $-448,648 |
| High | $7M | $-10,532 | $-804,347 | $-728,601 | $-688,925 | $-440,046 |
| EPS Avg | $-0.00 | $-0.00 | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
| Low | $-0.04 | $-0.00 | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
| High | $0.09 | $-0.00 | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
| Analysts (Rev / EPS) | 4 / 3 | 3 / 1 | 3 / 1 | 2 / 1 | 2 / 1 | 3 / 1 |